January 25, 2021

The lack of minority representation in clinical trials is often explained as an unwillingness of minority patients to become involved. However, a study on barriers to recruiting underrepresented populations to cancer clinical trials demonstrates that the researcher may be responsible for this outcome. This study and others have found that providing additional information relevant to...

We are living longer, and our population is increasingly aging. Despite a growing need for clinical trials that benefit seniors, the median age of clinical trial participants is decreasing. A recent study examining clinical trial enrollment of over 262,000 patients with common cancer types between 1994 and 2015 found that the difference in the median...

MONDAY, Jan. 25, 2021 (HealthDay News) — For individuals with type 2 diabetes, metabolic surgery is more effective than medical therapy for long-term control, according to a study published in the Jan. 23 issue of The Lancet. Geltrude Mingrone, M.D., from the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, and colleagues conducted a 10-year...

The inclusion of pregnant women in clinical trials has been one of the most contentious issues of modern science. While we have come a long way since the exclusion of all women of childbearing age, there is still hesitation among scientists to include pregnant women, a vulnerable population, in clinical trials [1]. After all, a...

Pooled relative risk of 0.988 for each increment of one cup of coffee per day revealed in meta-analysis of cohort studies Increased coffee consumption is associated with a reduced risk for prostate cancer, according to a review and meta-analysis published online Jan. 11 in BMJ Open. Xiaonan Chen, from Shengjing Hospital of China Medical University, and...

Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19 and may increase mortality, according to a study published online Jan. 20 in The BMJ. Viviane C. Veiga, M.D., Ph.D., from the BP-A Beneficência Portuguesa de São Paulo in Brazil, and colleagues conducted a...

The risk of getting prostate cancer is 75% higher for Black men than it is for white men, and it is more than twice as deadly. Now, research is helping to bring genetic risks for people of various racial and ethnic groups into focus. In doing so, dozens more risk factors that could better help...